Rutgers The State University Of New Jersey

Rutgers The State University Of New Jersey, operating through its Robert Wood Johnson Health Sciences School of Nursing division (doing business as RBHS-School of Nursing), is a non-profit, 1862 land-grant educational institution and a child entity of the parent Rutgers university system, headquartered in Newark, New Jersey, that receives federal research funding as a prime recipient for biomedical and health services research, with no competitive set-asides applied to most of its federal awards. The school competes on full-and-open basis across the National Institutes of Health system and other civilian health research agencies, receiving project grants and other assistance mechanisms rather than federal contracts.

Rutgers-Newark's federal research footprint centers on NIH-funded biomedical and clinical research. The school's portfolio spans basic science, translational research, and population health studies in infectious disease, oncology, neurology, immunology, aging-related disease, substance use and addiction, environmental health, maternal and child health, and behavioral health. Recent representative work includes a $35.194 million definitive contract awarded by the Food and Drug Administration in September 2026 for identification and performance assessment of medical devices in electronic health record data and development of a framework to enhance medical device integration in real-world evidence generation under Executive Order 14398, running through September 2031; a $3.297 million National Institute of Child Health and Human Development award to investigate mechanistic pathways linking gut microbiota alterations to neurodevelopmental impairment in HIV-exposed, uninfected infants; and a $1.413 million National Institute on Drug Abuse award to develop and test a telehealth-delivered motivational interviewing intervention for young adults who use electronic nicotine delivery systems. SCI-reported service contract work totaled $2.1 million in invoiced revenue across FY2023–FY2024, with median government-paid rates around $203.78 per hour and senior labor pricing through $312/hr, reflecting predominantly direct-delivery research staffing rather than subcontracted labor.

Federal research awards cluster heavily with the National Institutes of Health. The top five funding agencies by award count—the National Cancer Institute (145 awards, $509.1 million combined potential value), the National Institute of Allergy and Infectious Diseases (126 awards), the National Institute on Drug Abuse (79 awards), the National Heart Lung and Blood Institute (73 awards), and the National Institute on Aging (67 awards)—account for 37% of the school's 1,307 total awards and 83% of combined potential value. Recent activity shows 308 awards in calendar 2024, 266 in 2025, and 181 in 2026, with 297 awards facing completion in the next twenty-four months and combined potential recompete value of $25.9 million. The school operates as a prime recipient on 57% of awards (750) and participates as a sub-recipient on 43% (557), performing work across Newark, New Jersey; Piscataway, New Jersey; and named domestic and international sites. As a child entity within the Rutgers enterprise and the Robert Wood Johnson Health Sciences organizational structure, the school leverages institutional research infrastructure, clinical partnerships through RWJBarnabas Health System, clinical trial networks, and community-based relationships across northern New Jersey to support competitive federal research awards in biomedical science, health services research, and public health intervention development. The school has received multiple sub-recipient positions on NIH grants managed by peer research institutions including Johns Hopkins University, Yale University, Columbia University, University of Pittsburgh, and others, indicating integration into multi-site research consortia focused on infectious disease, cancer, aging, neurology, and substance use research.